Pharmaceutics (May 2020)

Biphasic Dissolution as an Exploratory Method during Early Drug Product Development

  • Daniela Amaral Silva,
  • Jozef Al-Gousous,
  • Neal M. Davies,
  • Nadia Bou Chacra,
  • Gregory K. Webster,
  • Elke Lipka,
  • Gordon L. Amidon,
  • Raimar Löbenberg

DOI
https://doi.org/10.3390/pharmaceutics12050420
Journal volume & issue
Vol. 12, no. 5
p. 420

Abstract

Read online

Dissolution testing is a major tool used to assess a drug product’s performance and as a quality control test for solid oral dosage forms. However, compendial equipment and methods may lack discriminatory power and the ability to simulate aspects of in vivo dissolution. Using low buffer capacity media combined with an absorptive phase (biphasic dissolution) increases the physiologic relevance of in vitro testing. The purpose of this study was to use non-compendial and compendial dissolution test conditions to evaluate the in vitro performance of different formulations. The United States Pharmacopeia (USP)-recommended dissolution method greatly lacked discriminatory power, whereas low buffer capacity media discriminated between manufacturing methods. The use of an absorptive phase in the biphasic dissolution test assisted in controlling the medium pH due to the drug removal from the aqueous medium. Hence, the applied non-compendial methods were more discriminative to drug formulation differences and manufacturing methods than conventional dissolution conditions. In this study, it was demonstrated how biphasic dissolution and a low buffer capacity can be used to assess in vitro drug product performance differences. This can be a valuable approach during the early stages of drug product development for investigating in vitro drug release with improved physiological relevance.

Keywords